At the European Angel Investor Summit 2025, a panel moderated by Xènia Colomer (EBAN) brought together leading voices in innovation and investment—Miguel Rodriguez of Octantis, Jesper Jarlbæk, President of EBAN, and Nicolás Galmarini, CEO of Nanogrow Biotech—to explore how corporate–startup collaborations shape investor confidence and startup growth potential.
The discussion emphasised that strategic alignment between startups and corporate partners often outweighs monetary considerations. Jesper Jarlbæk noted that Corporate Venture Capital (CVC) cycles can be volatile, urging founders to choose partners whose goals, engagement models, and track records align closely with their own. Understanding the logic of exits, acquisition intentions, and information rights is critical before signing any agreements.
Miguel Rodriguez highlighted the importance of trust-building through small, focused projects rather than rushing into expansive partnerships. Early-stage collaboration, he argued, should be structured as limited-scope pilots that allow both technical and business stakeholders to validate mutual value. Nicolás Galmarini added that in deep tech and biopharma, startups should prioritise early customers—often mid-size corporates—before pursuing investors, using short, deliverable-based work packages to demonstrate progress.
The panel also tackled governance, intellectual property, and execution dynamics. Founders were encouraged to design contracts resilient to sponsor turnover, maintain clear IP boundaries, and structure proof-of-concept ladders with defined metrics and follow-up checkpoints. Delegating clear technical and business points of contact within the partnership enhances agility and accountability.
Ultimately, the speakers agreed that successful corporate collaborations require disciplined execution, flexibility, and constant stakeholder engagement. When managed strategically, such partnerships not only strengthen a startup’s operational credibility but also increase its attractiveness to investors looking for risk-mitigated innovation opportunities.
